What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Heart failure
- Cardiology
G. Michael Felker spends much of his time researching Heart failure, Internal medicine, Cardiology, Intensive care medicine and Heart disease.
G. Michael Felker mostly deals with Ejection fraction in his studies of Heart failure.
His study looks at the relationship between Internal medicine and fields such as Endocrinology, as well as how they intersect with chemical problems.
His studies in Cardiology integrate themes in fields like Clinical endpoint and Blood pressure.
His research integrates issues of Management of heart failure, Epidemiology, Diuretic and Acute decompensated heart failure in his study of Intensive care medicine.
His Heart disease study combines topics in areas such as Functional recovery, Disease progression, Myocarditis, Inotrope and Transplantation.
His most cited work include:
- Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. (1223 citations)
- Diuretic Strategies in Patients with Acute Decompensated Heart Failure (987 citations)
- Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial (746 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Heart failure, Internal medicine, Cardiology, Intensive care medicine and Ejection fraction.
As a part of the same scientific study, G. Michael Felker usually deals with the Heart failure, concentrating on Placebo and frequently concerns with Clinical endpoint and Surgery.
His study in the fields of Renal function, Proportional hazards model, Acute decompensated heart failure and Serelaxin under the domain of Internal medicine overlaps with other disciplines such as In patient.
His Cardiology study frequently involves adjacent topics like Blood pressure.
The various areas that he examines in his Intensive care medicine study include Emergency department, Disease and Diuretic.
His studies deal with areas such as Valsartan, Prospective cohort study and Ventricular remodeling as well as Ejection fraction.
He most often published in these fields:
- Heart failure (92.15%)
- Internal medicine (77.27%)
- Cardiology (65.50%)
What were the highlights of his more recent work (between 2017-2021)?
- Heart failure (92.15%)
- Internal medicine (77.27%)
- Cardiology (65.50%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Heart failure, Internal medicine, Cardiology, Ejection fraction and Natriuretic peptide.
G. Michael Felker interconnects Biomarker, Clinical trial, Renal function and Intensive care medicine in the investigation of issues within Heart failure.
The Renal function study which covers Blood pressure that intersects with Proportional hazards model.
In his research on the topic of Internal medicine, Inotrope is strongly related with Placebo.
He studied Cardiology and Omecamtiv mecarbil that intersect with Contractility.
His research in Ejection fraction intersects with topics in Valsartan, Prospective cohort study and Diastole.
Between 2017 and 2021, his most popular works were:
- Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. (120 citations)
- Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury (104 citations)
- Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. (91 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Heart failure
- Cardiology
Heart failure, Internal medicine, Cardiology, Ejection fraction and Clinical trial are his primary areas of study.
His work carried out in the field of Heart failure brings together such families of science as Randomized controlled trial, Blood pressure and Intensive care medicine.
In general Internal medicine, his work in Hazard ratio, Biomarker, Confidence interval and Nesiritide is often linked to In patient linking many areas of study.
His Cardiology study incorporates themes from Tolerability and Renal function.
His study in Ejection fraction is interdisciplinary in nature, drawing from both Omecamtiv mecarbil, Cardiac function curve, Valsartan, Diastole and Inotrope.
His Clinical trial research includes elements of Large cohort, Outcomes research, Risk stratification, Proportional hazards model and Pharmacotherapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
